

Germany

Recent and planned developments in pharmaceutical policies 2025/2026

CHANGES IN PRICING

Confidential reimbursement price:

Available only for patented drugs, which

- Are new drugs
- with first contract closed after 01.01.2025 (limited until 30.06.2028)
- with delivered proof of research activity and research department in Germany

Deduction of 9% from reimbursement price

No external price referencing since 01.01.2025

Exception from regulations of § 130b Abs. 3 Social Code Book V ("Leitplanken") for patented drugs, if percentage of clinical study population in Germany with minimum of 5% (reviewed by G-BA (Federal Joint Committee))

CHANGES IN REIMBURSEMENT

Extension of biological and biosimilar substitution (since 01.04.2026)


New definitions of conditions for pharmacy for substitution of doctor-prescribed biological with a lower-cost product

Link: [Anlage VIIa](#)



OTHER CHANGES

- Suggestion of finance expert committee for reduction in costs of Statutory health insurance and increase in revenue
 - 66 suggestions over all sections (pharmaceuticals, hospitals, doctors, patients)
 - Suggestions for pharmaceuticals (examples):
 - Introduction of a dynamic manufacturer's discount
 - Revision of the Price-Volume Regulation
 - Suggestions for hospitals (examples):
 - Revision of "NUB" (new examination and treatment methods)
 - Obligatory second opinion in case of surgery treatments
 - Suggestions for patients (examples):
 - End of free marriage partner insurance
 - Higher patient fee's in pharmacy



All suggestions are under review and are subject to the decision of the Federal Government, which is expected at the end of April.

SPECIAL TOPIC:

Regulation, pricing and reimbursement of pharmaceutical combination products

"Kombinationsabschlag" –discount on combination therapies of patented products

Regulation: § 130e SGB V (social book No. 5) – in force since October 2024

G-BA (federal joint committee) determines the combination therapies which are subject to the combination discount according to Section 130e SGB V; refund between single health insurance funds and pharmaceutical companies (section 5 of resolution of new substance)

Pricing: Deduction of 20% of ex-factory price per package, applies when

- Combinations of patented medicines are prescribed at the same day or are dispensed on the same day
- Or
- Repeated switch (minimum of twice switches within 5 months)
- Exception: considerable additional benefit at least in one patient group for the combination therapy

Link: [2024-10-08_Regelung_Kombiabschlag_130e_SGB_V](#)

